SCHEMBL3449696

SCHEMBL3449696

CCOC(=O)c1cncc(-c2cnc(Nc3ccc(F)c(Cl)c3)nc2NCCN2CCOCC2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 7/20 0.46
AXL P30530 1/20 0.45
SYK P43405 1/20 0.45
MAP3K8 P41279 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
STK17A Q9UEE5 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
FYN P06241 1/20 0.43
MAPK13 O15264 1/20 0.42
PRKD3 O94806 1/20 0.42
PRKCG P05129 1/20 0.42
PRKCB P05771 1/20 0.42
SRC P12931 1/20 0.42
PRKCA P17252 1/20 0.42
PRKCH P24723 1/20 0.42
PRKCI P41743 1/20 0.42
MAPK12 P53778 1/20 0.42
PRKCE Q02156 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3461367 0.96 STK17A (0.46) EGFRAXLSYKMAP3K8STK17A
SCHEMBL3448660 0.93 AXL (0.53) EGFRAXLSTK17AERBB2BRD4
SCHEMBL3448151 0.91 AXL (0.46) EGFRAXLSTK17AERBB2BRD4
SCHEMBL3447664 0.90 EGFR (0.49) EGFRAXLSYKMAP3K8STK17A
SCHEMBL3448587 0.87 STK17A (0.50) EGFRAXLSYKSTK17AERBB2
SCHEMBL3449458 0.87 STK17A (0.45) EGFRAXLMAP3K8STK17AERBB2
SCHEMBL3448724 0.86 STK17A (0.44) EGFRAXLSTK17AERBB2BRD4
SCHEMBL3451485 0.85 STK17A (0.47) EGFRAXLMAP3K8STK17AFYN
SCHEMBL3448122 0.85 P2RY12 (0.46) EGFRSMN1; SMN2BRD4
SCHEMBL3451827 0.85 CSNK2A1 (0.49) EGFRAXLSTK17AERBB2STK17B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD EGFR 2771/4885AXL 2812/4885SYK 804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.